# A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients

> **NCT06583993** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 9 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** HNF4α srRNA

## Key facts

- **NCT ID:** NCT06583993
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-07
- **Primary completion:** 2026-05
- **Final completion:** 2026-07
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06583993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06583993, "A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06583993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*